Catalyst Wire Dossier Catalyst Wire Dossier

Olmesartan/Amlodipine/Rosuvastatin combination

· Daewoong Pharmaceutical Co. Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Olmesartan/Amlodipine/Rosuvastatin combination, covering 2022-01-11 to 2022-01-11. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia [Phase 3]

See pricing